|Description||BAY-1895344 is a selective ATR (ataxia-telangiectasia and Rad3 related protein) inhibitor that inhibits proliferation of a broad spectrum of human tumor cell lines (median IC50 = 78 nM). BAY-1895344 is developed for the treatment of patients with advanced solid tumors and lymphomas, and it is undergoing a phase I clinical trial of safety and tolerability for cancer patients.|
|Brife Description||ATR (ataxia-telangiectasia and Rad3 related protein) inhibitor, ATR, advanced solid tumors and lymphomas|
|Solubility||Soluble in DMSO.|
|Storage||Store in a cool and dry place and at 0-4 ℃ for short term (days to weeks) or -66 ℃ for long term (months to years).|
|Application||A selective ATR (ataxia-telangiectasia and Rad3 related protein) inhibitor used for the treatment of advanced solid tumors and lymphomas.|
|Shelf Life||2 years|
VE-821 is the first highly selective and potent ATR inhibitor. VE-821 inhibited radiation- and gemcitabine-induced phosphorylation of Chk1, confirming inhibitio...
BAY-1895344 is a selective ATR (ataxia-telangiectasia and Rad3 related protein) inhibitor that inhibits proliferation of a broad spectrum of human tumor cell li...
In vitro, AZ20 decreases pChk1 Ser345, pChk1 Ser317 and pChk1 Ser296 levels in a concentration-dependent manner.
VX-970, also known as VE-822, is an potent ATR inhibitor. VE-822 inhibited ATR in vitro and in vivo. VE-822 decreased maintenance of cell-cycle checkpoints, inc...
ETP-46464 is a cell-permeable quinoline-containing heterotricyclic compound that acts as a potent inhibitor against mTOR, ATR, DNA-PK, PI 3-Kα, and ATM (IC50= 0...
AZD6738 is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2.